Stoke Therapeutics, Inc.
STOK
$26.10
-$3.94-13.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.82M | 158.57M | 22.61M | 4.89M | 4.83M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.82M | 158.57M | 22.61M | 4.89M | 4.83M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 13.82M | 158.57M | 22.61M | 4.89M | 4.83M |
| SG&A Expenses | 15.26M | 14.65M | 12.84M | 12.69M | 13.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.12M | 47.33M | 36.27M | 34.90M | 34.17M |
| Operating Income | -27.30M | 111.24M | -13.65M | -30.00M | -29.34M |
| Income Before Tax | -23.48M | 114.16M | -10.48M | -26.43M | -25.70M |
| Income Tax Expenses | -- | 1.28M | -- | -- | -- |
| Earnings from Continuing Operations | -23.48M | 112.88M | -10.48M | -26.43M | -25.70M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.48M | 112.88M | -10.48M | -26.43M | -25.70M |
| EBIT | -27.30M | 111.24M | -13.65M | -30.00M | -29.34M |
| EBITDA | -26.85M | 111.72M | -13.13M | -29.46M | -28.79M |
| EPS Basic | -0.40 | 1.95 | -0.18 | -0.47 | -0.46 |
| Normalized Basic EPS | -0.25 | 1.23 | -0.11 | -0.29 | -0.29 |
| EPS Diluted | -0.40 | 1.90 | -0.18 | -0.47 | -0.46 |
| Normalized Diluted EPS | -0.25 | 1.20 | -0.11 | -0.29 | -0.29 |
| Average Basic Shares Outstanding | 58.35M | 57.86M | 57.03M | 56.34M | 55.77M |
| Average Diluted Shares Outstanding | 58.35M | 59.40M | 57.03M | 56.34M | 55.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |